Armando Santoro
0000-0003-1709-9492
Humanitas University
639 papers found
Refreshing results…
P05.08 High-grade gliomas and immunotherapeutic early phase clinical trials: a single-center experience
Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience
Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases
Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies
Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes
Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Ps1246 Graft Source and Pre‐transplant Disease Status Are the Main Variables Affecting the Outcome of T Cell‐replete Haploidentical Transplantation With Post‐transplant Cyclophosphamide for Hodgkin Lymphoma
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer
Developing an adolescent and young adult (AYA) cancer program in an Italian adult high-volume cancer center.
Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.
Screening of BRCA2 mutated men for detection of prostate cancer: Preliminary results from a national high volume cancer center.
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience.
HER2-positive breast cancer and CNS metastases: Prognostic factors and clinical outcome
Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction
FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
Missing publications? Search for publications with a matching author name.